CLINICAL_TRIALS research · 2025-08-05

Clinical Trial Update: CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients [Phase 3]

Open-label Phase 3 clinical trial CHIP-AML22/Master for newly diagnosed pediatric de novo acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Princess Maxima Center for Pediatric Oncology | Conditions: Acute Myeloid Leukemia in Children | Phase 3 | Status: RECRUITING